ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference
ProMIS Neurosciences (Nasdaq: PMN), a clinical-stage biotechnology company specializing in antibody therapeutics for neurodegenerative diseases, has announced its participation in the 7th Annual Evercore HealthCONx Conference. CEO Neil Warma will engage in a fireside chat on December 3, 2024, at 1:20 p.m. ET in Coral Gables, FL.
The company focuses on developing treatments for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The fireside chat will be accessible via webcast on the company's website and remain available for at least 30 days after the event.
ProMIS Neurosciences (Nasdaq: PMN), un'azienda biotecnologica in fase clinica specializzata in terapie anticorpali per malattie neurodegenerative, ha annunciato la sua partecipazione alla 7ª Conferenza Annuale Evercore HealthCONx. Il CEO Neil Warma parteciperà a una chiacchierata informale il 3 dicembre 2024, alle 13:20 ET a Coral Gables, FL.
L'azienda si concentra nello sviluppo di trattamenti per la malattia di Alzheimer, la sclerosi laterale amiotrofica (SLA) e l'atrofia multisistemica (AMS). La chiacchierata informale sarà accessibile tramite webcast sul sito web dell'azienda e rimarrà disponibile per almeno 30 giorni dopo l'evento.
ProMIS Neurosciences (Nasdaq: PMN), una empresa biotecnológica en etapa clínica especializada en terapias con anticuerpos para enfermedades neurodegenerativas, ha anunciado su participación en la 7.ª Conferencia Anual Evercore HealthCONx. El CEO Neil Warma participará en una charla informal el 3 de diciembre de 2024, a la 1:20 p.m. ET en Coral Gables, FL.
La empresa se enfoca en desarrollar tratamientos para la enfermedad de Alzheimer, la esclerosis lateral amiotrófica (ELA) y la atrofia multisistémica (AMS). La charla informal estará disponible a través de un webcast en el sitio web de la empresa y permanecerá accesible durante al menos 30 días después del evento.
ProMIS Neurosciences (Nasdaq: PMN)는 신경퇴행성 질환을 위한 항체 치료제에 전문화된 임상 단계의 생명공학 회사로, 제7회 Evercore HealthCONx 회의에 참여한다고 발표했습니다. CEO Neil Warma는 2024년 12월 3일 오후 1시 20분 ET에 플로리다주 코럴 게이불스에서 대화 형식의 토론에 참여할 예정입니다.
회사는 알츠하이머병, 근위축성 측삭경화증(ALS), 다계통 위축증(MSA) 치료제를 개발하는 데 주력하고 있습니다. 대화형 토론은 회사 웹사이트에서 웹캐스트로 이용 가능하며, 행사 종료 후 최소 30일간 제공됩니다.
ProMIS Neurosciences (Nasdaq: PMN), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies par anticorps pour les maladies neurodégénératives, a annoncé sa participation à la 7e Conférence Annuelle Evercore HealthCONx. Le PDG Neil Warma s'engagera dans une discussion informelle le 3 décembre 2024, à 13h20 ET à Coral Gables, FL.
L'entreprise se concentre sur le développement de traitements pour la maladie d'Alzheimer, la sclérose latérale amyotrophique (SLA) et l'atrophie multisystémique (AMS). La discussion sera accessible par webdiffusion sur le site internet de l'entreprise et restera disponible pendant au moins 30 jours après l'événement.
ProMIS Neurosciences (Nasdaq: PMN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Antikörpertherapeutika für neurodegenerative Erkrankungen spezialisiert hat, hat seine Teilnahme an der 7. jährlichen Evercore HealthCONx-Konferenz bekannt gegeben. CEO Neil Warma wird am 3. Dezember 2024 um 13:20 Uhr ET in Coral Gables, FL an einem informellen Gespräch teilnehmen.
Das Unternehmen konzentriert sich auf die Entwicklung von Behandlungen für Alzheimer, amyotropher Lateralsklerose (ALS) und multiple Systematrophie (MSA). Das Gespräch wird über einen Webcast auf der Unternehmenswebsite zugänglich sein und bleibt mindestens 30 Tage nach der Veranstaltung verfügbar.
- None.
- None.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3, 2024 at 1:20 p.m. ET in Coral Gables, FL.
A live webcast of the fireside chat may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com, and will be available for at least 30 days following the event.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company’s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. PMN310, the Company’s lead product candidate for the treatment of AD, is a differentiated, humanized monoclonal antibody that has been designed to specifically bind toxic Aβ oligomers and to not bind plaque or monomers. Oligomers are known to drive disease progression in AD and PMN310 appears to be the only antibody to selectively bind oligomers, which is expected to support better safety and efficacy. PMN 310 has successfully completed a Phase 1a clinical study and ProMIS expects to initiate a Phase 1b clinical trial in AD patients by year end 2024. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.
For further information:
Visit us at www.promisneurosciences.com.
Please submit media inquiries to info@promisneurosciences.com.
For Investor Relations, please contact:
Precision AQ (formerly Stern IR)
Anne Marie Fields, Managing Director
annemarie.fields@precisionaq.com
Tel. 212-362-1200
FAQ
When is ProMIS Neurosciences (PMN) presenting at the Evercore HealthCONx Conference 2024?
What diseases does ProMIS Neurosciences (PMN) target in their research?
How can I watch ProMIS Neurosciences (PMN) fireside chat at the Evercore Conference?
